{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:53Z","timestamp":1750392653844,"version":"3.41.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016009","name":"Rising Tide Foundation for Clinical Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"Rogel Cancer Center, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clbc.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:15:10Z","timestamp":1738916110000},"page":"464-471.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing Cannabidiol Use in a Breast Cancer Population"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-7070","authenticated-orcid":false,"given":"Nicole M.G.","family":"Fleege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley T.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin F.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clbc.2025.02.003_bib0001","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: origins and biosynthesis","volume":"25","author":"G\u00fclck","year":"2020","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.clbc.2025.02.003_bib0002","first-page":"1","article-title":"Mechanisms of action and pharmacokinetics of cannabis","volume":"25","author":"Chayasirisobhon","year":"2020","journal-title":"Perm J."},{"issue":"6","key":"10.1016\/j.clbc.2025.02.003_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS Neurol Disord Drug Targets."},{"issue":"2","key":"10.1016\/j.clbc.2025.02.003_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpainsymman.2012.07.014","article-title":"An open-label extension study to investigate the long-term safety and tolerability of THC\/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics","volume":"46","author":"Johnson","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.clbc.2025.02.003_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pmn.2018.12.006","article-title":"Cannabinoids in pain treatment: an overview","volume":"20","author":"Mallick-Searle","year":"2019","journal-title":"Pain Manag Nurs"},{"issue":"4","key":"10.1016\/j.clbc.2025.02.003_bib0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bcpt.13710","article-title":"A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)","volume":"130","author":"Peng","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"22","key":"10.1016\/j.clbc.2025.02.003_bib0007","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clbc.2025.02.003_bib0008","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.32059","article-title":"The role of cancer in marijuana and prescription opioid use in the United States: a population-based analysis from 2005 to 2014","volume":"125","author":"Tringale","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.02.003_bib0009","first-page":"285","article-title":"Pharmacology and legal status of cannabidiol","volume":"56","author":"Brunetti","year":"2020","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.clbc.2025.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","volume":"42","author":"Braun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clbc.2025.02.003_bib0011","doi-asserted-by":"crossref","first-page":"e24060","DOI":"10.1200\/JCO.2024.42.16_suppl.e24060","article-title":"The impact of cannabidiol (CBD) on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)","volume":"42","author":"Fleege","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2025.02.003_bib0012","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpain.2020.12.001","article-title":"Cannabidiol use for fibromyalgia: prevalence of use and perceptions of effectiveness in a large online survey","volume":"22","author":"Boehnke","year":"2021","journal-title":"J Pain"},{"key":"10.1016\/j.clbc.2025.02.003_bib0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2474-7-82","article-title":"Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients","volume":"7","author":"Lauridsen","year":"2006","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"10.1016\/j.clbc.2025.02.003_bib0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"},{"issue":"21","key":"10.1016\/j.clbc.2025.02.003_bib0015","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1002\/cncr.34922","article-title":"Cannabis use among adults undergoing cancer treatment","volume":"129","author":"Azizoddin","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2025.02.003_bib0016","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cncr.33906","article-title":"A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment","volume":"128","author":"Weiss","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clbc.2025.02.003_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00520-023-07881-6","article-title":"Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access","volume":"31","author":"McClure","year":"2023","journal-title":"Support Care Cancer"},{"issue":"18","key":"10.1016\/j.clbc.2025.02.003_bib0018","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.33646","article-title":"Prevalence of cannabis use among individuals with a history of cancer in the United States","volume":"127","author":"Cousins","year":"2021","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.clbc.2025.02.003_bib0019","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/cncr.34793","article-title":"Cannabis use among cancer survivors in 22 states: results from the Behavioral Risk Factor Surveillance System, 2020","volume":"129","author":"Sedani","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2025.02.003_bib0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00520-023-07662-1","article-title":"MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events","volume":"31","author":"To","year":"2023","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2025.02.003_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"year":"2023","series-title":"Evaluating Symptom Clusters in Patients with Breast Cancer Experiencing Aromatase Inhibitor-Associated Musculoskeletal Symptoms [abstract]","author":"Fleege","key":"10.1016\/j.clbc.2025.02.003_bib0022"},{"issue":"17","key":"10.1016\/j.clbc.2025.02.003_bib0023","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.clbc.2025.02.003_bib0024","unstructured":"Administration. UFaD. 2016 Warning letters and test results for cannabidiol-related products. Accessed April 12, 2024, https:\/\/www.fda.gov\/news-events\/public-health-focus\/warning-letters-and-test-results-cannabidiol-related-products"},{"key":"10.1016\/j.clbc.2025.02.003_bib0025","unstructured":"FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Accessed April 12, 2024, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms."},{"issue":"2","key":"10.1016\/j.clbc.2025.02.003_bib0026","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/2049463720922884","article-title":"Barriers to the wider adoption of medicinal cannabis","volume":"14","author":"Alexander","year":"2020","journal-title":"Br J Pain"},{"key":"10.1016\/j.clbc.2025.02.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.pecinn.2022.100044","article-title":"Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: a qualitative study","volume":"1","author":"Sharma","year":"2022","journal-title":"PEC Innov"},{"issue":"11","key":"10.1016\/j.clbc.2025.02.003_bib0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/OP.22.00080","article-title":"Cannabis use in patients with cancer: a clinical review","volume":"18","author":"Worster","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"S1","key":"10.1016\/j.clbc.2025.02.003_bib0029","doi-asserted-by":"crossref","first-page":"90s","DOI":"10.1002\/j.1552-4604.2002.tb06008.x","article-title":"Endocrine effects of marijuana","volume":"42","author":"Brown","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clbc.2025.02.003_bib0030","first-page":"175","article-title":"Marijuana, the endocannabinoid system and the female reproductive system","volume":"89","author":"Brents","year":"2016","journal-title":"Yale J Biol Med."},{"issue":"7","key":"10.1016\/j.clbc.2025.02.003_bib0032","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.02.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35459","article-title":"Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window","volume":"131","author":"Reiner","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.02.003_bib0034","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1532-5415.2009.02714.x","article-title":"Elderly breast cancer survivors accurately self-report key treatment information","volume":"58","author":"Yen","year":"2010","journal-title":"J Am Geriatr Soc"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T01:15:33Z","timestamp":1750382133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1526820925000333"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.02.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing Cannabidiol Use in a Breast Cancer Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}